Caedo Oncology AS

As we wrap up an exciting year, we’re thrilled to reflect on the incredible milestones we’ve achieved together: 🌟 This year, we: - Celebrated the publication of our first patent, with three more in the pipeline. - Advanced our CMC efforts with the production and testing of initial stable cell lines. - Collaborated with national and international experts, pushing boundaries in our field. - Continued preclinical development on our lead candidate, defining its initial target indication. - Secured funding from the Norwegian Research Council, fueling our innovation and progress. These achievements are a testament to the dedication of our team and partners. We’re inspired and energized to carry this momentum into 2025. 🎉🎊 Wishing everyone a joyful holiday season and a successful new year 🎄 . Here’s to another year of growth, collaboration, and impact! #Immunotherapy #newdrug #cancertreatment #CD47 #biggoals

What an incredible time at the SITC Annual Meeting in sunny Houston! ☀️ Our CEO, Kjetil Hestdal, MD, PhD, and Scientist, Sittana Matar, had a fantastic time connecting with brilliant minds and diving into inspiring discussions about the development of CO-005. The energy, innovation, and collaboration were unmatched! And to top it all off, we had a blast with the CheckPoints band—because science and music are the perfect combo! 🎶🎸 We’re already looking forward to SITC 2025, where we’ll return with even more exciting data to share. 🚀 #SITC2024 #ImmunoOncology #Innovation #Collaboration #ScienceMeetsMusic #3DPrinting #FusionProtein #OncologyResearch

We are presenting at SITC 2024 in Houston! 📍 Location: Exhibit Halls A & B, George R. Brown Convention Center Poster Presentations Poster 1: 📝 Title: CO-005, a novel anti-CD47 fusion protein with improved safety and efficacy in lymphoma therapies 📅 Date: Friday, Nov. 8, 2024 📑 Abstract Number: 515 Poster 2: 📝 Title: The Importance of Innovative Design in Enhancing the Safety of Next-Generation Anti-CD47 Therapeutics 📅 Date: Saturday, Nov. 9, 2024 📑 Abstract Number: 1122 Come by for an insightful discussion—see you there! #SITC2024 #Immunotherapy #cancertreatment

🎉 We’re back at SITC 2024! Will we see you there? 🎉 We’re excited to invite you to visit our posters at SITC 2024 in Houston, Texas! Come by to check out our latest findings on the development of CO-1 and its fusion protein, which provides an improved safety profile. We will also be sharing key strategies to mitigate the safety challenges associated with CD47 mAbs. Our CEO, Kjetil Hestdal, MD, PhD, and Research Scientist, Sittana Matar, will be there to present the posters and engage in insightful discussions. We would love to hear your feedback and exchange ideas! If you’re interested in setting up a casual meeting to dive deeper into these topics, feel free to connect with us beforehand. 🗓 Poster Presentations: 📍Location: Exhibit Halls A & B, George R. Brown Convention Center Poster 1: 📝 Title: CO-005, a novel anti-CD47 fusion protein with improved safety and efficacy in Lymphoma therapies 📅Date: Friday, Nov. 8, 2024 📑 Abstract Number: 515 Poster 2: 📝 Title: The Importance of Innovative Design in Enhancing the Safety of the Next Generation Anti-CD47 Therapeutics 📅Date: Saturday, Nov. 9, 2024 📑 Abstract Number: 1122 Looking forward to seeing you there and engaging in some exciting conversations! #SITC2024 #Immunotherapy #CD47 #CancerResearch #Oncology #CaedoOncology #Houston

🌟 Exciting News from Caedo Oncology! 🌟 We’re proud to announce that Caedo Oncology has secured 16M NOK in funding from Forskningsrådet (Norwegian Research Council) to advance a novel immunotherapy for B-cell malignancies. The project focuses on: 1.    Better understanding the mechanism of action of CO-1. 2.    A non-GLP safety study in humanized mouse model. 3.    GMP development of the CO-1 fusion protein with our CMO partner. Additionally, we are collaborating with Oslo University Hospital (OUH) to explore the impact of CO-1 on multiple myeloma cells from naïve, relapsed, and refractory patients. This achievement highlights the incredible teamwork and dedication of everyone involved. We’re excited to continue pushing toward better treatments for patients! #Forskningsrådet #Immunotherapy #Cancer #OUH #Innovation.

🚀 Exciting news! The global antibody therapeutics market is projected to reach USD 497.5 billion by 2029, with a CAGR of 14.5% from 2024 to 2029. Caedo Oncology is listed among the many organizations contributing to this expanding market. Being recognized alongside industry giants like F. Hoffmann-La Roche Ltd, Abbvie Inc., and Johnson & Johnson Services highlights our commitment to advancing the biopharmaceutical sector. Together, we are driving the future of healthcare. 🌍💉 #Biopharma #AntibodyTherapeutics #HealthcareInnovation #IndustryGrowth

🚀 Exciting news! The global antibody therapeutics market is projected to reach USD 497.5 billion by 2029, with a CAGR of 14.5% from 2024 to 2029. We are thrilled to be part of this wave of innovation and remain fully committed to advancing developments in the field. #Biopharma #AntibodyTherapeutics #HealthcareInnovation #IndustryGrowth

🎉 Exciting News Alert! 🎉 We are thrilled to announce a significant milestone for our team at Caedo oncology! Our first patent has been published, marking a significant achievement in our journey. 🏆 This patent covers the development of monovalent CD47 binding proteins, a crucial advancement in our field. But that's not all – we have even more exciting developments on the horizon! Three additional patents are in the pipeline, each covering different designs, including the innovative design of our lead candidate aimed at mitigating hematological risks associated with anti-CD47 therapies. This achievement wouldn't have been possible without the dedication and hard work of our entire team. A big congratulations to everyone involved, especially our co-inventors Kjetil Hestdal, MD, PhD, @Rolf D Pettersen, PhD. , Nina Richartz, Sittana Matar, and Seham Skah, PhD., whose contributions have been invaluable. 🙌 If you're interested in reading the patent, the link is in the comment section below. Here's to celebrating this milestone and looking forward to even more groundbreaking innovations ahead! 🚀 #Innovation #Patent #TeamWork #MilestoneAchievement

Thrilled to share some exciting company updates! 🚀✨ The year kicked off on a high note as we moved into our new office at Forskningsparken, and it already feels like home. But that's not all – our team's hard work has already shown results with the successful production and testing of the initial stable cell line production. We're now in full swing to produce the GLP batch for our lead product, CO-1. Special thanks to our CMC head, Thomas Meum Andersen, consultant extraordinaire, Tiffany Rau, and R&D team for their invaluable contributions Here's to continued success and growth on this exciting journey! 🌟👏 #companyupdates #milestoneachieved #teamworkwins

🎉 Welcoming 2024 at Caedo Oncology! 🚀 Excited to continue our mission in developing groundbreaking cancer drugs. 🌟 Thanks to our amazing team and partners for a successful year. Here's to more breakthroughs, innovation, and impact in the fight against cancer! #NewYear2024 #CancerResearch #Innovation #Teamwork